Postmenopausal hypertension: Mechanisms and therapy

Hypertension

Volumn 54, Issue 1, 2009, Pages 11-18

  Barton, Matthias ^a   Meyer, Matthias R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; IRBESARTAN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; THIAZIDE DIURETIC AGENT;

AGING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENTIATION; ESTROGEN SYNTHESIS; GLOMERULOSCLEROSIS; HORMONAL THERAPY; HORMONE ACTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MENSTRUAL CYCLE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; POSTMENOPAUSE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; SALT INTAKE; SHORT SURVEY; SODIUM RESTRICTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ESTROGENS; FEMALE; HUMANS; HYPERTENSION; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RISK FACTORS;

EID: 67649855149     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.120022     Document Type: Short Survey

References (89)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.
2. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291-1297.
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
4. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: 1206-1252.
6. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.
7. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.
8. Wassertheil-Smoller S, Anderson G, Psaty BM, Black HR, Manson J, Wong N, Francis J, Grimm R, Kotchen T, Langer R, Lasser N. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension. 2000;36:780-789.
9. Bramlage P, Pittrow D, Wittchen HU, Kirch W, Boehler S, Lehnert H, Hoefler M, Unger T, Sharma AM. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17:904-910.
10. Ma J, Stafford RS. Screening, treatment, and control of hypertension in US private physician offices, 2003-2004. Hypertension. 2008;51: 1275-1281.
11. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
12. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53:688-708.
13. Meyer MR, Haas E, Barton M. Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension. 2006;47:1019-1026.
14. Rang S, Wolf H, Montfrans GA, Karemaker JM. Non-invasive assessment of autonomic cardiovascular control in normal human pregnancy and pregnancy- associated hypertensive disorders: a review. J Hypertens. 2002;20:2111-2119.
15. Landahl S, Bengtsson C, Sigurdsson JA, Svanborg A, Svardsudd K. Age-related changes in blood pressure. Hypertension. 1986;8: 1044-1049.
16. Mueck AO, Seeger H. Effect of hormone therapy on blood pressure in normotensive and hypertensive postmenopausal women. Maturitas. 2004;49:189-203.
17. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension. 2008;51:952-959.
18. Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens. 1989;3:427-433.
19. Amigoni S, Morelli P, Parazzini F, Chatenoud L. Determinants of elevated blood pressure in women around menopause: results from a cross-sectional study in Italy. Maturitas. 2000;34:25-32.
20. Izumi Y, Matsumoto K, Ozawa Y, Kasamaki Y, Shinndo A, Ohta M, Jumabay M, Nakayama T, Yokoyama E, Shimabukuro H, Kawamura H, Cheng Z, Ma Y, Mahmut M. Effect of age at menopause on blood pressure in postmenopausal women. Am J Hypertens. 2007;20: 1045-1050.
21. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab. 2008;93:1276-1284.
22. Langrish JP, Mills NL, Bath LE, Warner PE, Webb DJ, Kelnar CJ, Critchley HOD, Newby DE, Wallace WHB. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension. 2009;53:805-811.
23. Mercuro G, Zoncu S, Saiu F, Mascia M, Melis GB, Rosano GM. Menopause induced by oophorectomy reveals a role of ovarian estrogen on the maintenance of pressure homeostasis. Maturitas. 2004;47: 131-138.
24. Barton M, Meyer MR, Haas E. Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits? Arterioscler Thromb Vasc Biol. 2007;27:1669-1672.
25. Reckelhoff JF. Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. Hypertension. 2005;45: 170-174.
26. Ashraf MS, Vongpatanasin W. Estrogen and hypertension. Curr Hypertens Rep. 2006;8:368-376.
27. Arias-Loza PA, Jazbutyte V, Pelzer T. Genetic and pharmacologic strategies to determine the function of estrogen receptor alpha and estrogen receptor beta in cardiovascular system. Gend Med. 2008;5(suppl A):S34-S45.
28. Ogawa S, Emi M, Shiraki M, Hosoi T, Ouchi Y, Inoue S. Association of estrogen receptor beta (ESR2) gene polymorphism with blood pressure. J Hum Genet. 2000;45:327-330.
29. Peter I, Shearman AM, Zucker DR, Schmid CH, Demissie S, Cupples LA, Larson MG, Vasan RS, D'Agostino RB, Karas RH, Mendelsohn ME, Housman DE, Levy D. Variation in estrogen-related genes and cross-sectional and longitudinal blood pressure in the Framingham Heart Study. J Hypertens. 2005;23:2193-2200.
30. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol. 2008;70:165-190.
31. Haas E, Meyer MR, Schurr U, Bhattacharya I, Minotti R, Nguyen HH, Heigl A, Lachat M, Genoni M, Barton M. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension. 2007;49:1358-1363.
32. Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu C, Gao X, Mueller-Guerre L, Marjon NA, Gut A, Minotti R, Meyer MR, Amann K, Ammann E, Perez-Dominguez A, Genoni M, Clegg DJ, Dun NJ, Resta T, Prossnitz ER, Barton M. Regulatory role of G-protein coupled estrogen receptor for vascular function and obesity. Circ Res. 2009;104:288-291.
33. Meyer MR, Haas E, Barton M. Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis. Gend Med. 2008;5(suppl A):S19-S33.
34. Pechere-Bertschi A, Burnier M. Female sex hormones, salt, and blood pressure regulation. Am J Hypertens. 2004;17:994-1001.
35. Coggins CH, Breyer Lewis J, Caggiula AW, Castaldo LS, Klahr S, Wang SR. Differences between women and men with chronic renal disease. Nephrol Dial Transplant. 1998;13:1430-1437.
36. Xiao S, Gillespie DG, Baylis C, Jackson EK, Dubey RK. Effects of estradiol and its metabolites on glomerular endothelial nitric oxide synthesis and mesangial cell growth. Hypertension. 2001;37:645-650.
37. Zheng F, Plati AR, Potier M, Schulman Y, Berho M, Banerjee A, Leclercq B, Zisman A, Striker LJ, Striker GE. Resistance to glomerulosclerosis in B6 mice disappears after menopause. Am J Pathol. 2003;162: 1339-1348.
38. Hernandez Schulman I, Raij L. Salt sensitivity and hypertension after menopause: role of nitric oxide and angiotensin II. Am J Nephrol. 2006;26:170-180.
39. Myers J, Morgan T. The effect of sodium intake on the blood pressure related to age and sex. Clin Exp Hypertens A. 1983;5:99-118.
40. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27:481-490.
41. Bigazzi R, Bianchi S, Baldari G, Campese VM. Clustering of cardiovascular risk factors in salt-sensitive patients with essential hypertension: role of insulin. Am J Hypertens. 1996;9:24-32.
42. Miyoshi A, Suzuki H, Fujiwara M, Masai M, Iwasaki T. Impairment of endothelial function in salt-sensitive hypertension in humans. Am J Hypertens. 1997;10:1083-1090.
43. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, Inenaga T, Kimura G. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997;350:1734-1737.
44. Barton M, Mullins JJ, Bailey MA, Kretzler M. Role of endothelin receptors for renal protection and survival in hypertension: waiting for clinical trials. Hypertension. 2006;48:834-837.
45. Schulman IH, Aranda P, Raij L, Veronesi M, Aranda FJ, Martin R. Surgical menopause increases salt sensitivity of blood pressure. Hypertension. 2006;47:1168-1174.
46. Scuteri A, Lakatta EG, Anderson DE, Fleg JL. Transdermal 17 beta-oestradiol reduces salt sensitivity of blood pressure in postmenopausal women. J Hypertens. 2003;21:2419-2420.
47. Maric C, Sandberg K, Hinojosa-Laborde C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. J Am Soc Nephrol. 2004;15:1546-1556.
48. Maric C, Xu Q, Sandberg K, Hinojosa-Laborde C. Age-related renal disease in female Dahl salt-sensitive rats is attenuated with 17 betaestradiol supplementation by modulating nitric oxide synthase expression. Gend Med. 2008;5:147-159.
49. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause. 2007;14:373-384.
50. Dubey RK, Tofovic SP, Jackson EK. Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther. 2004;308:403-409.
51. Masi CM, Hawkley LC, Berry JD, Cacioppo JT. Estrogen metabolites and systolic blood pressure in a population-based sample of postmenopausal women. J Clin Endocrinol Metab. 2006;91:1015-1020.
52. Sutherland TE, Schuliga M, Harris T, Eckhardt BL, Anderson RL, Quan L, Stewart AG. 2-Methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer. Clin Cancer Res. 2005;11:1722-1732.
53. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994;121:936-941.
54. Fisman EZ, Tenenbaum A, Shapira I, Motro M, Pines A. The acute effects of sublingual estradiol on left ventricular diastolic function in normotensive and hypertensive postmenopausal women. Maturitas. 1999;33:145-152.
55. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
56. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
57. August P, Oparil S. Hypertension in women. J Clin Endocrinol Metab. 1999;84:1862-1866.
58. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
59. Nair GV, Chaput LA, Vittinghoff E, Herrington DM. Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease. Chest. 2005;127:1498-1506.
60. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
61. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res. 2005;66:295-306.
62. Zaydun G, Tomiyama H, Hashimoto H, Arai T, Koji Y, Yambe M, Motobe K, Hori S, Yamashina A. Menopause is an independent factor augmenting the age-related increase in arterial stiffness in the early postmenopausal phase. Atherosclerosis. 2006;184:137-142.
63. Barton M, Dubey RK. Postmenopausal hormone-replacement therapy. N Engl J Med. 2002;346:63-65.
64. Collins P, Flather M, Lees B, Mister R, Proudler AJ, Stevenson JC, for the WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. Eur Heart J. 2006;27:1046-1053.
65. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein-a cross-sectional population survey. Thromb Haemost. 2001;86: 550-556.
66. Ichikawa J, Sumino H, Ichikawa S, Ozaki M. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens. 2006;19:744-749.
67. Akkad AA, Halligan AW, Abrams K, al-Azzawi F. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Obstet Gynecol. 1997;89: 97-103.
68. Vongpatanasin W, Tuncel M, Mansour Y, Arbique D, Victor RG. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation. 2001;103:2903-2908.
69. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3:324-327.
70. Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Wunder D, Imthurn B, Rosselli M. Medroxyprogesterone abrogates the inhibitory effects of estradiol on vascular smooth muscle cells by preventing estradiol metabolism. Hypertension. 2008;51:1197-1202.
71. Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G, Colditz GA, Stampfer MJ. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation. 1996;94:483-489.
72. Djerassi C, Miramontes L, Rosenkranz G, Sondheimer F. Synthesis of 19-Nov-17alpha-ethynyltestosterone and 19-Nor-17alpha-methyltestosterone. J Am Chem Soc. 1954;76:4092-4094.
73. Portaluppi F, Pansini F, Manfredini R, Mollica G. Relative influence of menopausal status, age, and body mass index on blood pressure. Hypertension. 1997;29:976-979.
74. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352:1138-1145.
75. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, Kaaja R, Mikkola T, Palacios S, Preston R, Simon T, Stevenson J, Stramba-Badiale M. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J. 2007;28:2028-2040.
76. Preston RA Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women. Climacteric. 2007;10(suppl 1):32-41.
77. da Costa LS, de Oliveira MA, Rubim VS, Wajngarten M, Aldrighi JM, Rosano GM, Neto CD, Gebara OC. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women. Am J Cardiol. 2004;94: 1453-1456.
78. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885.
79. Nestel PJ, Clifton PM, Noakes M, McArthur R, Howe PR. Enhanced blood pressure response to dietary salt in elderly women, especially those with small waist: hip ratio. J Hypertens. 1993;11:1387-1394.
80. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER III, Simons-Morton DG, Karanja N, Lin PH, for the DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3-10.
81. Rossi R, Nuzzo A, Origliani G, Modena MG. Metabolic syndrome affects cardiovascular risk profile and response to treatment in hypertensive postmenopausal women. Hypertension. 2008;52:865-872.
82. Pines A, Fisman EZ. Hypertension in menopausal women-a special case, for special treatment? Gynecol Endocrinol. 2001;15:397-405.
83. Mirza FS, Ong P, Collins P, Okamura K, Gerhard-Herman M, Williams GH, Seely EW. Effects of estradiol and the angiotensin II receptor blocker irbesartan on vascular function in postmenopausal women. Menopause. 2008;15:44-50.
84. Meyer MR, Haas E, Prossnitz ER, Barton M. Non-genomic regulation of vascular cell function and growth by estrogen. Mol Cell Endocrinol. In press.
85. Prossnitz ER, Barton M. Signaling, physiological functions and clinical relevance of the G-protein-coupled estrogen receptor GPER. Prostaglandis Other Lipid Mediat. In press.
86. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the GPR30 agonist G-1 decreases blood pressure in ovariectomized mREN2 Lewis rats. Endocrinology. In press.
87. Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002;40:441-447.
88. Lurbe E, Torro I, Aguilar F, Alvarez J, Alcon J, Pascual JM, Redon J. Added impact of obesity and insulin resistance in nocturnal blood pressure elevation in children and adolescents. Hypertension. 2008;51: 635-641.
89. Sakuragi S, Abhayaratna K, Gravenmaker KJ, O'Reilly C, Srikusalanukul W, Budge MM, Telford RD, Abhayaratna WP. Influence of adiposity and physical activity on arterial stiffness in healthy children: the lifestyle of our kids study. Hypertension. 2009;53:602-604.